CG
ACHN

Cutler Group’s Achillion Pharmaceuticals ACHN Stock Holding History

Cutler Group’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-3,100
Closed -$1K – 6419
2017
Q3 		$1K Buy
+3,100
New +$13.8K ﹤0.01% 5677
2016
Q4 		– Sell
-13,800
Closed -$6K – 7713
2016
Q3 		$6K Sell
13,800
-900
-6% -$7.65K ﹤0.01% 4867
2016
Q2 		$9K Sell
14,700
-12,700
-46% -$109K ﹤0.01% 4337
2016
Q1 		$17K Sell
27,400
-6,200
-18% -$45.4K ﹤0.01% 3500
2015
Q4 		$54K Buy
+33,600
New +$305K ﹤0.01% 2377

Other funds holding ACHN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Cutler Group's ACHN Position: Q1 2018 in Review

Cutler Group sold out of Achillion Pharmaceuticals (ACHN) in Q1 2018, closing a stake of 354 shares — an estimated $1K sold.

Cutler Group first reported a position in ACHN in Q4 2015 and held it in 6 quarters. The position peaked at $259K in Q4 2015. 127 funds tracked by Wall St. Rank hold ACHN as of Q1 2018.

  • Cutler Group reported no remaining Achillion Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Cutler Group sold 354 Achillion Pharmaceuticals shares in Q1 2018, an estimated $1K.
  • Cutler Group first reported a position in Achillion Pharmaceuticals in Q4 2015 and held it in 6 quarters.
  • Cutler Group's Achillion Pharmaceuticals position peaked at $259K in Q4 2015.
  • 127 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2018.

Based on Cutler Group's 13F filing for Q1 2018, filed 11 May 2018.